TSHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TSHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Taysha Gene Therapies's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.16.
Taysha Gene Therapies's EPS (Basic) for the three months ended in Mar. 2024 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.16.
Taysha Gene Therapies's EPS without NRI for the three months ended in Mar. 2024 was $-0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.62.
During the past 3 years, the average EPS without NRIGrowth Rate was 42.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 5 years, Taysha Gene Therapies's highest 3-Year average EPS without NRI Growth Rate was 42.70% per year. The lowest was 42.70% per year. And the median was 42.70% per year.
The historical data trend for Taysha Gene Therapies's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EPS (Diluted) | - | -3.40 | -4.64 | -3.78 | -0.96 |
Taysha Gene Therapies Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EPS (Diluted) | Get a 7-Day Free Trial | -0.28 | -0.38 | -0.93 | 0.26 | -0.10 |
For the Biotechnology subindustry, Taysha Gene Therapies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's PE Ratio distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Taysha Gene Therapies's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
Diluted EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-111.566 | - | 0) | / | 116.121 | |
= | -0.96 |
Taysha Gene Therapies's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as
Diluted EPS (Q: Mar. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-24.061 | - | 0) | / | 231.249 | |
= | -0.10 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (NAS:TSHA) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Taysha Gene Therapies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Alison S Long | director | KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Kamran Alam | officer: Chief Financial Officer | 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118 |
Sean P. Nolan | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Phillip B. Donenberg | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Session R.a. Ii | 10 percent owner | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Sukumar Nagendran | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Astellas Pharma Inc. | 10 percent owner | 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411 |
Audentes Therapeutics, Inc. | 10 percent owner | 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108 |
Suyash Prasad | officer: CMO and Head of R&D | C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104 |
Laura Sepp-lorenzino | director | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
Kathleen Reape | director | C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235 |
From GuruFocus
By PRNewswire • 10-03-2023
By Marketwired • 08-14-2023
By Marketwired • 10-24-2023
By Marketwired • 06-28-2023
By Marketwired • 08-14-2023
By Value_Insider Value_Insider • 11-29-2022
By Marketwired • 11-07-2023
By GlobeNewswire GlobeNewswire • 10-25-2022
By Value_Insider Value_Insider • 10-25-2022
By sperokesalga sperokesalga • 06-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.